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ABSTRACT 
Methodological issues of how to use health state utility values (HSUV) in decision models arise 
frequently including the most appropriate evidence to use as the baseline (e.g. the baseline health 
state utility values associated with avoiding a particular health condition or event), how to capture 
changes due to adverse events and how to appropriately capture uncertainty in progressive 
conditions where the expected change in quality of life is likely to be monotonically decreasing over 
time.    
 
As preference-based measures provide different values when collected from the same patient it is 
important to ensure that all HSUVs used within a single model is obtained from the same instrument 
where ever possible.  When people enter the model without the condition of interest (e.g. primary 
prevention of cardiovascular disease, screening or vaccination programmes), appropriate age and 
gender adjusted health state utility values from people without the particular condition should be 
used as the baseline. General population norms may be used as a proxy if the exact condition-
specific evidence is not available.  Individual discrete health states should be used for serious 
adverse reactions to treatment and the corresponding HSUVs sourced as normal.   Care should be 
taken to avoid double counting when capturing the effects for both less severe adverse reactions 
(e.g. itchy skin rash or dry cough), or more severe adverse events (e.g. fatigue in oncology) . 
 
Transparency in reporting standards for both the justification of the evidence used and any 
 ?ĂĚũƵƐƚŵĞŶƚƐ ?is important to increase ƌĞĂĚĞƌƐ ? confidence that the evidence used is the most 
appropriate available. 
 
Key points for decision makers  
x Health state utility values (HSUVs) used in decision models should be obtained from the 
same data source and collected or predicted from the same preference-based measure 
where ever possible.   
x Serious adverse reactions to treatment should be represented by individual discrete health 
states and care should be taken to avoid double counting for adverse reactions (e.g. itchy 
skin rash or dry cough) 
x If no suitable evidence is identified in the literature reviews, the preferred approach would 
be to conduct an independent study to collect the required HSUVs.  If this is not possible, 
ĞǀŝĚĞŶĐĞĨƌŽŵƉĞŽƉůĞǁŝƚŚĂ ?ƐŝŵŝůĂƌ ?ĐŽŶĚŝƚŝŽŶ ?ŽƌĂǀŝŐŶĞƚƚĞƐƚƵĚǇ are options but both are 
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to be considered inferior, and a wide range of sensitivity analyses should be conducted to 
determine if the model results are robust to the values used. 
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1. Introduction 
Populating decision models with health state utility values (HSUVs) is not an exact science and there 
are unresolved issues relating to both the evidence available (which may not always be the ideal 
evidence) and the practical technical problems of how to use the evidence available in decision 
models.  These issues arise time after time and while there is some methodological research in the 
area, this is limited and recommendations are sparse.  As a consequence, this article indicates best 
practice based on the limited evidence available and personal experience of the authors and is not 
intended to be prescriptive. 
 
It is important to reiterate that irrespective of the specific requirements of policy makers and 
reimbursement agencies, it is extremely important that HSUVs within a decision model are obtained 
using the same preference based measure (PBM) (or are all estimated from the same valid mapping 
function 
[1]
) as HSUVs obtained from different PBMs are not directly comparable due to the 
differences in HSUVs, even when completed by the same person 
[2,3,4,5,6,7]
.   When multiple sources of 
high quality relevant evidence are available, ideally a full meta-analysis would be conducted, 
although for many models (e.g. osteoporosis ) this is not be possible due to heterogeneity in the 
studies 
[8,9]
.  When multiple HSUVs are available, the final choice should be clearly justified to avoid 
selection bias. 
 
This article examines the use of HSUV evidence collected in clinical trials used in decision analytic 
models (DAM) to estimate the effectiveness of the intervention; the evidence used to represent the 
baseline / counterfactual health states; adjustments to available evidence to account for age, 
gender, adverse effects on health related quality of life (HRQoL) associated with interventions; 
characterising uncertainty in HSUVs; and options available when the required HSUVs are not 
available from a measure of HRQoL.  Estimating HSUVs for comorbid conditions are discussed 
separately 
[10]
. 
 
2. HSUVs collected in RCT used to estimate effectiveness  
The advantages and disadvantages of efficacy randomised control trials (RCTs) as sources of data for 
estimating HSUVs are discussed elsewhere 
[11,12,13]
.  The main advantage stems from the internal 
validity arising from a RCT since the patients differ only in the treatment they receive.  However, 
there are numerous reasons why RCTs may not provide the most appropriate evidence for 
estimating HSUVs for a decision model.  HRQoL evidence may not be collected; the preferred 
preference-based measure may not be used; the sample size or numbers of events observed may be 
 5 
 
too small to subgroup for all the individual health states within the decision model; the effectiveness 
evidence may be from a meta-analysis of several studies and it may be impossible to pool HRQoL 
evidence [
14
]; or the collection times of the evidence may not capture the different clinical events 
(e.g. it can be difficult to capture flares in inflammatory conditions).  Furthermore, the patient 
sample and/or treatment protocols (for the new and control regimes) may not reflect those in the 
decision model representing the consequences for patients in the real world.  The role of HSUVs 
from RCTs will be specific to the context.  
 
However, irrespective of whether it is used in the decision model, if HSUVs are available from RCTs 
used to estimate effectiveness, then this evidence should be reported in some form to illustrate that 
the intervention under evaluation (or the comparator) does not have an independent detrimental 
effect on HRQoL over and above the effect associated with discrete clinical events.  For example, 
pharmacological interventions prescribed to treat prostatic hyperplasia can cause sexual dysfunction 
[15]
. 
 
3. Baseline (or counterfactual) evidence 
Decision models used to assess the cost-effectiveness of interventions in health care typically assess 
benefits in terms of the incremental quality adjusted life-years (QALYs) accrued with avoiding a 
clinical event (e.g. a heart attack in people with a history of cardiovascular disease, or a hip 
replacement in people with osteoarthritis), a reduction in progression of a chronic condition (e.g. a 
reduction of pain and increase in function in people with ankylosing spondylitis), an increase in life 
expectancy (e.g. in people with cancer), or the alleviation or reduction in risk of contracting a 
particular condition (e.g. vaccinations for seasonal influenza or screening programs for cancer).  
Consequently, in addition to mean HSUVs obtained from people experiencing particular clinical 
events, procedures or conditions, DAMs also require HSUVs from people who do not experience the 
event, procedure or condition (see Box 1 for examples) to determine the potential incremental gain 
in avoiding an event or alleviating a condition. 
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Box 1  Examples of different baseline HSUVs 
Example 1 
In a primary prevention, screening or vaccination model, most people will enter the model in a 
 ?ĚŝƐĞĂƐĞ-ĨƌĞĞ ? ŚĞĂůƚŚ ƐƚĂƚĞ ?  &Žƌ ĞǆĂŵƉůĞ ? ŝŶ ŝƚƐ ƐŝŵƉůĞƐƚ ĨŽƌŵ ? Ă ĚĞĐŝƐŝŽŶ ŵŽĚĞů evaluating the 
benefits of a vaccination programme against the influenza virus would involve three health states: 
no influenza, influenza and death.  In this instance analysts will require HSUVs for people 
experiencing influenza and HSUVs from the general population not currently experiencing influenza.  
Due to the nature of the condition, the effect on HRQoL is likely to be short-term in the vast majority 
of cases, with no residual long-term effects.  Typically, evidence from people who do not currently 
have influenza will not be available, and in this instance it would be appropriate to use age and 
ŐĞŶĚĞƌƐƚƌĂƚŝĨŝĞĚ,^hsƐĨƌŽŵƚŚĞŐĞŶĞƌĂůƉŽƉƵůĂƚŝŽŶĂƐĞǀŝĚĞŶĐĞĨŽƌƚŚĞ ?ĚŝƐĞĂƐĞĨƌĞĞ ?ŚĞĂůƚŚƐƚĂƚĞ ? 
Example 2 
Lipid lowering interventions reduce the risk of cardiovascular events and can be prescribed for 
primary prevention (i.e. in patients with no history of cardiovascular disease) or for secondary 
prevention (i.e. in patients with a history of cardiovascular disease).  Consequently, in addition to the 
acute and long-term HSUVs from people who have experienced a particular cardiovascular event 
(e.g. heart attack or stroke), analysts modelling the quality adjusted life years (QALY) benefits 
associated with these interventions will also require HSUVs from people who have not experienced 
the particular event.  In a primary prevention analysis (example 2a) this would be evidence from 
people with no history of cardiovascular disease (stratified by age and gender) while in a secondary 
prevention analysis (example 2b) this would be evidence from people who have a history of 
cardiovascular disease but no recent cardiovascular event (stratified by age and gender). 
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3.1 Alternative forms of evidence that can be used to depict the baseline /counterfactual 
There are three forms of evidence that have been used as the baseline: a constant value of full 
health (i.e. EQ-5D = 1 irrespective of age or gender), age and gender stratified evidence from the 
general population (includes all evidence irrespective of health status), and age and gender stratified 
evidence from individuals who do not have the condition (or event) of interest.  Assuming a baseline 
of full health is inappropriate as, on average, the mean HSUV is never equal to one irrespective of 
age or gender (Table 1) 
[16]
.  Using the previous examples (Box 1), if a heart attack is avoided in 
patients with existing cardiovascular disease there may still be a detrimental effect on HRQoL 
associated with the underlying condition (e.g. the residual long-term effects of a previous stroke or 
heart attack).  Similarly, if influenza is avoided, given the target population (e.g. elderly and people 
with diabetes etc.), the recipients of the vaccinations are likely to have at least one other prevalent 
chronic health condition.  Consequently using a baseline of full health (i.e. HSUV = 1) will 
overestimate the benefits of treatments (See Box 2 for an example).  
 
Table 1  UK EQ-5D-3L age-adjusted population norms 
[17,18]
 
Age Male Female 
20 0.9536 0.9324 
25 0.9449 0.9236 
30 0.9344 0.9132 
35 0.9223 0.9011 
40 0.9086 0.8874 
45 0.8932 0.8720 
50 0.8761 0.8549 
55 0.8574 0.8362 
60 0.8370 0.8158 
65 0.8150 0.7938 
70 0.7913 0.7701 
75 0.7659 0.7447 
80 0.7389 0.7177 
Estimated using: ܧܳ- ?ܦ ൌ  ?Ǥ ? ? ? ? ? ? ?൅  ?Ǥ ? ? ? ? ? ? ? ? ?ൈ ݈݉ܽ݁ െ  ?Ǥ ? ? ? ? ? ? ?ൈ ܽ݃݁ െ  ?Ǥ ? ? ? ? ? ? ?ൈ ܽ݃݁H?  Eqn1 
 
While evidence from people without the specific condition or event is the preferred evidence, this 
form of evidence is limited and can be difficult to source.  It has been suggested that general 
population norms could be used as the baseline if evidence is not available from people without a 
particular health condition 
[17]
.  This is plausible if the prevalence of the condition is relatively small 
as revised mean HSUVs obtained when excluding the relatively small subgroup will probably not 
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differ substantially from the mean HSUVs from the full sample of the general population.  As these 
values are likely to be very slightly lower than those obtained when excluding a particular 
population, the benefits of interventions will be underestimated (see Box 2 for an example).   
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Box 2  Total and incremental QALYs associated with avoiding a heart attack 
Estimating the QALYs gained when avoiding a heart attack using alternative evidence for the 
baseline (assuming the event occurs at the age of 50 years, and using a 50 year horizon) 
Baseline trajectory EQ-5D 
Full health ൌ  ? 
Population with no history of CVD ൌ  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ െ  ?Ǥ ? ? ? ? ? ? ? ൈ H?[18] Eqn1 
General population ൌ  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ?ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ H? 
Mean EQ-5D for heart attack ൌ  ?Ǥ ? ? ? ? 
Mean age for heart attack ൌ  ? ?Ǥ ? 
Mean EQ-5D at age 66.6 years for 
pop
n
 with no history of CVD 
ൌ  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ?ൈ  ? ?Ǥ ? െ  ?Ǥ ? ? ? ? ? ? ൈ  ?Ǥ ?H?ൌ  ?Ǥ ? ? ? ? 
Multiplier ൌ  ?Ǥ ? ? ? ?ൊ  ?Ǥ ? ? ? ?ൌ  ?Ǥ ? ? ? ?ሺሻ 
Mean EQ-5D at age 66.6 years for 
gen pop
n
 
ൌ  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ?ൈ  ? ?Ǥ ? െ  ?Ǥ ? ? ? ? ? ? ? ൈ ?Ǥ ?H?ൌ  ?Ǥ ? ? ? ? 
Multiplier ൌ  ?Ǥ ? ? ? ?ൊ  ?Ǥ ? ? ? ?ൌ  ?Ǥ ? ? ? ? 
 
Total and incremental QALYs accrued over 50 years using the alternative baseline evidence 
 Baseline of full health 
Baseline from people with 
no history of CVD 
Baseline from 
general population 
 
No heart 
attack 
Heart 
attack 
No heart 
attack 
Heart  
attack 
No 
heart 
attack 
Heart 
attack 
Total QALYs  50 36.95 39.27 35.13 38.08 34.85 
Incremental QALY 
gain 
 13.05  4.14  3.23 
 
The total QALYs accrued over a 50 year horizon are calculated for a male who does not experience a 
heart attack (Person A), and for a male who experiences a heart attack (Person B), using three 
alternative profiles for the baseline.  For example, using a baseline of full health Person A would 
accrue 50 QALYs (50 x 1), while Person B would accrue 36.95 QALYs (50 x 0.7390), giving an 
incremental QALY of 13.05 (50  W 36.95).Using evidence from patients who have no history of CVD as 
the baseline, Patient A would accrue 39.27 QALYs ( ?  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ?ൈ  െH?H?H? ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ H?) while Patient B would accrue 35.13 QALYs 
( ?  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ H?H?H?H? ൈ  ?Ǥ ? ? ? ?ሻ giving 
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an incremental QALY of 4.14 (39.27  W 35.13). The QALY gains using evidence from the general 
population are calculated using the same methodology: Patient A accrues 38.08 QALYs 
( ?  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ H?H?H?H? ), Patient B accrues 
34.85 ( ?  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ  െ  ?Ǥ ? ? ? ? ? ? ? ൈ H?H?H?H? ൈ  ?Ǥ ? ? ? ? ), 
giving an incremental QALY gain of 3.23 (38.08  W 34.85). 
 
As can be seen, the incremental QALYs associated with avoiding a heart attack differ substantially.  
Using the most appropriate evidence, obtained from people with no history of CVD, the incremental 
QALY gain associated with avoiding a single heart attack is 4.14, compared to 13.05 when using a 
baseline of full health and 3.23 when using evidence from the general population. 
NB: The evidence used to derive the HSUV (0.7390) was obtained from a sample who indicated they 
had a history of a heart attack.  The sample were not sub-grouped by time since event, and in an 
actual cost-effectiveness model it would be important to consider this as quality of life may change 
over time 
[18,19]
. 
Key: CVD  W cardiovascular disease; QALY  W quality adjusted life year 
 
Using a case-study in primary prevention of cardiovascular disease, researchers have shown that the 
baseline evidence can affect the results to such an extent that these could influence a policy decision 
based on a given cost per QALY threshold 
[18]
.  Using a baseline of full health resulted in a higher 
QALY gain and thus lower cost per QALY compared to using age-adjusted profiles.  This was 
particularly true of older aged cohorts. 
 
3.2 Appropriateness of general population norms 
One study reported that general population norms are appropriate to use as the baseline for many 
prevalent chronic health conditions such as cardiovascular disease, diabetes and arthritic conditions 
[17]
.  Using broadly defined self-reported health conditions and EQ-5D-3L data collected in the Health 
Survey for England, and comparing age-stratified scores (people without a particular condition 
compared to the general population), the authors reported that general population age-adjusted 
norms could be used if condition specific evidence was not available.  Estimates of age-gender 
norms obtained from the Health Survey for England (see Table 1) are only relevant for decision 
models using EQ-5D-3L HSUVs obtained using the UK tariff weights (NB: As the conditions in this 
survey are self-reported there are arguments against the robustness of this evidence when using 
condition specific evidence) 
[20]
.  While there are equivalent published general population norms 
suitable for other settings 
[21]
, to our knowledge, evidence from individuals who do not have 
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particular conditions are not currently available for other preference-based measures or settings.  
However, many countries now conduct large national surveys which include data on HRQoL and 
condition at the individual level 
[21]
, and equivalent condition specific datasets could be estimated 
from these as and when required.  If the required condition specific evidence is not available, then a 
range of sensitivity analyses should be performed using evidence from the general population as one 
end of a range of plausible values. 
 
In summary, evidence obtained from cohorts without the health condition (or event) of interest is 
the ideal evidence to model the trajectory of the baseline over time.  However, age and gender 
stratified evidence from the general population may be a good proxy (and are preferred over using a 
constant baseline of full health) when these data are not available. 
 
4.  Adjustments to HSUVs 
Despite the substantial volume of published HSUVs, analysts are frequently faced with the dilemma 
of having less than ideal evidence.  For example, a cross-sectional review of HRQoL evidence used in 
the National Institute for Health and Care Excellence (NICE) submissions (n = 46 Health Technology 
Assessments (HTAs) during 2004-2008) reported that over one-third (36%) of the HSUVs (n = 284) 
used in the associated decision models (n = 71) had been adjusted in some way 
[22]
.  The main 
reasons for adjustments were reported to be age, adverse events and disease progression.  The 
authors reported a lack of clarity in reporting and it was suggested that the number was likely to be 
higher if actual adjustments in the decision analytic models were clearly reported in the HTAs or the 
associated journal articles.  They also reported a wide range in methodological variation in the 
methods used to adjust values.  Seventy-two percent of adjustments were made by either adding or 
subtracting a value from the original HSUV (some values appeared to be arbitrarily chosen); 18% 
multiplied the original HSUV by another utility value; and 10% incorporated a multivariate analysis.  
While intuitively, multivariate might appear to be the preferred option, there was no indication of 
which method would produce the most accurate results and the authors concluded that guidance 
was required to clarify the appropriateness of adjustments and the preferred methods for 
undertaking these.  However, to our knowledge such guidelines do not exist as yet. 
 
4.1 Adjustments to account for differences in age and gender 
In order to capture the full benefits of treatments, many decision models assess the QALYs accrued 
over a lifetime-horizon.  As mentioned previously, ignoring the reduction in HRQoL due to age will 
over-estimate the benefits of interventions.  If age and gender stratified HSUVs are used as the 
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baseline (as in example 1 above, see table 1), then there is generally no reason to make any 
additional adjustments for these.  It should be noted that the literature shows HSUVs for females are 
almost always lower than for males irrespective of the measure used 
[21].
  Consequently, when 
modelling an entirely female population (e.g. hormone replacement therapy for menopausal 
women), this should be accounted for by using evidence from female cohorts.  The potential equity 
implications of women having lower HSUVs is an issue that should be handled externally by policy 
decision makers. 
 
4.2 Detrimental effects on HRQoL associated with adverse reactions to treatments 
Many interventions cause adverse reactions and evidence on possible side-effects is collected 
routinely in clinical studies to support safety requirements for regulatory authorities such as the 
FDA.  Some adverse reactions are acute clinical events such as the gastro-intestinal bleeds associated 
with long-term steroid use; others are more chronic in nature such as the persistent dry cough 
associated with ACE-inhibitors, or the itchy skin rash associated with barbiturates and penicillin.  
While acute events will generally have an obvious detrimental effect on HRQoL, less serious side-
effects may be more difficult to quantify, particularly when using generic measures as they may be 
insensitive to the small changes in quality of life associated with these side effects. 
 
There are often no universally accepted standard definitions that can be used to classify adverse 
reactions to medical interventions, and severity definitions tend to be specific to the clinical study.  
Table 2 provides exemplars of two sets of definitions used 
[23,24]
.  The non-standardisation can cause 
uncertainty as to which adverse events should be captured in decision models.  It has been 
suggested that HSUVs should include decrements associated with grade 3-4 adverse events 
[25]
.  
Given the definitions below (grade 3: severe, grade 4: life threatening or disabling), it is likely that 
these would be modelled as discrete health states within the decision model.  Consequently the 
effect on HRQoL is likely to be significant and the required HSUV would need to be collected from 
people experiencing the event rather than making an adjustment to a HSUV.   
 
However, there are also occasions (such as the itchy skin rash) where less severe adverse reactions 
may have an independent effect on HRQoL that should be captured in the decision model.  In these 
instances, it is important that the effect on HRQoL is not double counted.  For example, if all the 
HSUVs in the decision model are obtained from recipients of the treatment inducing the adverse 
reaction, then it is inappropriate to include an additional decrement on top.  Conversely, assuming 
that grade 3 and 4 adverse events are described by discrete health states, and the HSUVs for all 
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health states are obtained from the literature (i.e. from people not receiving the intervention), it 
may be appropriate to apply an additional decrement to these to account for any detrimental 
treatment effect associated with less severe adverse reactions.  Both the inclusion or exclusion of 
less serious side effects should be justified, and sensitivity analyses performed to determine if the 
model results are robust to these. 
 
One way of exploring the magnitude of effect of adverse events would be to present subgroup 
analysis of HSUVs from an associated clinical trial to demonstrate any potential significant 
differences.  This could be achieved by comparing across treatment arms, or by comparing subjects 
who experience the adverse reaction with those who do not.  Subject to sample sizes, the decision 
to include AEs within the economic model could be informed by analysing trial data separately for 
patients with and without the grade 3 or 4 AEs.  The estimates of HSUVs used for this form of 
analysis do not necessarily need to come from the same measure as used for the HSUVs in the 
decision model.  If there is no significant difference, then there is no reason to adjust the HSUVs in 
the model.  If a negative independent treatment effect is observed, a threshold analysis could be 
performed to determine the magnitude of effect required for the incremental cost-effectiveness 
ratio (ICER) to go above the cost per QALY threshold.  
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Table 2  Exemplar definitions of adverse event severity definitions 
Severity Detailed definition 
Source: Deng, 2011 
[23]
 
Mild 
Awareness of signs and symptoms, but easily tolerated and are of minor irritant 
causing no loss of time from normal activities.  Symptoms do not required therapy 
or a medical intervention; signs and symptoms are transient 
Moderate 
Events introduce a low level of inconvenience or concern to the participant and may 
interfere with daily activities, but are usually improved by simple therapeutic 
measures; moderate experiences may cause some interference with functioning  
Severe 
Events ŝŶƚĞƌƌƵƉƚƚŚĞƉĂƌƚŝĐŝƉĂŶƚ ?ƐŶŽƌŵĂůĚĂŝůǇĂĐƚŝǀŝƚŝĞƐĂŶĚŐĞŶĞƌĂůůǇƌĞƋƵŝƌĞ
systemic drug therapy or other treatment; they are usually incapacitating 
Source: Sibille et al, 2010 
[24] 
Grade 1 Mild AE 
Grade 2 Moderate AE 
Grade 3 Severe AE 
Grade 4 Life-threatening or disabling AE 
Grade 5 Death related to AE 
Key: AE  W adverse events 
 
Additional research is required to inform guidelines in this area.  Table 3 provides an overview of 
several areas where adjustments are frequently made to HSUVs and may be used as a checklist of 
things to consider prior to making adjustments. 
 
Table 3 Checklist of considerations prior to adjusting HSUVs 
Adjustment Summary of things to consider 
Gender In general, HSUVs for females are lower than for 
age matched males. 
Does the evidence sample match the gender 
distribution used in the model. 
Age There is a natural decline in HSUVs by age. 
When using a lifetime horizon, consider if you 
need to adjust for age. 
HSUVs may decline over time in chronic 
progressive conditions.  Adjusting for age on top 
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of an observed decline in HSUVs may double 
count the effects of age as older patients are 
generally more likely to be in severe health 
states than younger patients in progressive 
conditions. 
Adverse events Some adverse events may not have an 
independent effect on HRQoL and may be safely 
ignored. 
Some adverse events associated with 
interventions may have an independent effect 
on HRQoL. 
Some generic measures may be insensitive small 
changes in HSUVs associated with specific 
adverse event.  
Is there evidence from an alternative measure 
that the adverse event in question has an 
independent effect on HRQoL. 
If the HSUVs are collected from a sample 
receiving the intervention of interest, applying 
an additional detriment for the adverse event 
may double count the effects of the adverse 
event.   
Time since event The time since the event (e.g. surgical 
intervention, discrete health condition) may 
have an independent effect on HRQoL. 
Check the time since event in the sample with 
that modelled. 
 
 
5. Alternative options if the required HSUVs are not available 
When cost-utility analyses first started to inform policy (1990s-early 2000s), HSUVs were rarely 
collected in clinical studies.  At that time it could be extremely difficult to identify any evidence on 
HRQoL for a specific condition, and it was particularly difficult to source any preference-based 
HSUVs from the literature.  Historically, when suitable evidence was not available, analysts would 
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have either presented results in terms of the cost per life year (i.e. they would have ignored the 
effects on HRQoL), or they would have used evidence from vignettes to populate decision models.   
 
Fortunately, the increase in the number of policy decision agencies requiring outputs in terms of the 
cost per QALY has had the consequence of increasing the evidence base reporting HSUVs, 
particularly for more prevalent health conditions.  The numbers of condition specific preference-
based measures (CSPBMs) and mapping studies between measures have also increased substantially 
in recent years (the latter predominantly after the NICE 2008 guide stated a preference for EQ-5D 
evidence 
[26]
).  Consequently, compared to fifteen or twenty years ago, it is now relatively rare that 
there is no evidence at all on HRQoL for a particular condition.  However, this situation does still 
occur and primarily happens for less prevalent health conditions and particularly for rare orphan 
conditions (e.g. lysosomal acid lipase deficiency where HSUVs collected from patients with non-
alcoholic steatohepatitis was used in the absence of HSUVs from the former condition) (NICE STA 
ongoing at time of publication 
[27]
).  
 
When all options have been exhausted in terms of literature reviews and mapping possibilities, the 
preferred approach would always be to conduct an independent study to collect the required HSUVs 
in the patient population of interest.  However, this form of primary research cannot always be 
undertaken due to either fiscal or time constraints.  The options in these situations are either to use 
,^hsƐŽďƚĂŝŶĞĚĨƌŽŵƉĞŽƉůĞǁŝƚŚĂ ?ƐŝŵŝůĂƌ ?ĐŽŶĚŝƚŝŽŶŽƌƚŽĐŽŶĚƵĐƚĂǀŝŐŶĞƚƚĞƐƚƵĚǇ ?These latter 
forms of evidence, and in particular evidence obtained from vignettes, should be considered as a last 
resort when all other possible sources have been exhausted (see Rowen et al for further information 
on vignettes 
[28]
).  In both cases, to avoid criticism, it is paramount to justify the approach by 
thoroughly documenting and reporting the literature reviews conducted.  It is equally important to 
perform an exhaustive series of univariate sensitivity analyses together with a threshold analysis to 
demonstrate both the potential effect on the ICER and to identify the HSUVs required to achieve 
relevant cost per QALY thresholds respectively.  When using evidence obtained from vignettes, any 
ĞǀŝĚĞŶĐĞĨƌŽŵ ?ƐŝŵŝůĂƌ ?ĐŽŶĚŝƚŝŽŶƐƐŚŽƵůĚďĞƵƚŝůŝƐĞĚŝŶ ƵŶŝǀĂƌŝĂƚĞƐĞŶƐŝƚŝǀŝƚǇĂŶĂůǇƐŝƐ ? 
 
6. Characterising uncertainty in HSUVs 
It is now standard practice to explore the uncertainty surrounding parameters used in decision 
models through univariate sensitivity, threshold analyses, and probabilistic sensitivity analyses using 
Monte-Carlo simulations.  The results, such as cost-effectiveness acceptability curves, are used to 
inform the decision uncertainty in the central estimate.  As the ICER is a ratio, and the denominator 
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is the incremental QALY gain, results can sometimes be extremely sensitive to changes in HSUVs, 
particularly when the central estimate for the incremental QALY gain is small.  Conversely, in 
decision models where the majority of the QALY gain is accrued from treatment induced reductions 
in mortality, the results from decision models can be robust to small adjustments in HSUVs. 
 
6.1  Forms of uncertainty 
There are several sources of uncertainty in HSUVs including: the preference-weights used in the 
tariff, the beta coefficients in mapping functions, the variance around independent mean HSUVs, the 
variance around correlated HSUVs, and the uncertainty around results from meta-analyses 
[9]
. 
 
Uncertainty in preference weights: Capturing the uncertainty in preference weights requires access 
to individual level data and the variance covariance matrix for the algorithm used to estimate the 
HSUVs.  This uncertainty is more likely to be characterised when conducting an economic evaluation 
alongside a clinical study and to our knowledge the uncertainty in the preference-weights is rarely or 
ever included in DAMs.  One study assessed the effect of including this parameter uncertainty in the 
utilities associated with the treatment of ruptured aneurysms 
[29]
.  The results were compared with 
those obtained generated using standard bootstrapped data from a clinical trial sample (n = 1633).  
The authors reported little difference in the estimated uncertainty around the utilities and 
concluded the parameter uncertainty may be more influential on smaller valuation sets or when 
using value sets estimated using different methods.  Research is required on additional data to 
determine the potential effect ignoring this uncertainty may have on resulting ICERs. 
 
Uncertainty in mapping functions: The uncertainty in the beta coefficients from mapping functions 
are captured using the associated variance covariance matrix.  This matrix takes into account both 
the uncertainty in the point estimates and the correlation between these.  When using published 
evidence, if the required matrix is not reported (and is not available from the author), the 
uncertainty in the individual coefficients (but not the correlation between the sampled values) may 
be explored using the reported mean and standard error. 
 
Uncertainty in mean HSUVs: Uncertainty in independent HSUVs may be characterised 
independently using the distributions discussed below.  However, it is not appropriate to sample 
independently when generating values for HSUVs known to have a monotonic relationship.  
Examples might be where health states are defined by disease severity, whereby the HSUV for the 
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most severe health state would be expected to be lower than the HSUV for the least severe health 
state. 
 
Uncertainty in correlated HSUVs 
Where the relationship between HSUVs is known to be monotonic (e.g. when health states are 
defined by severity), analysts have been known to use the same random number for each HSUV in 
an attempt to account for possible correlation.  However, this underestimates the magnitude of 
uncertainty and is inappropriate 
[30] ?  KŶĞ ĂƉƉƌŽƉƌŝĂƚĞ ŵĞƚŚŽĚ ǁŽƵůĚ ďĞ ƚŽ ƵƐĞ ƚŚĞ  ?ŝĨĨĞƌĞŶĐĞ
ŵĞƚŚŽĚ ?ĂƐƐƵŵŵĂƌŝƐĞĚŝŶBox 3 (interested readers can see Stevenson et al, 2017 for more details 
and a worked example) 
[30]
.  This is an area where additional research looking at the possible 
relationship between the decrement and the observed value for the health states is required. 
 
Box 3  Example using difference method to estimate HSUVs for correlated health states 
[30]
 
Given two health states known to have a monotonic relationship for HSUVs:  
x health state A (the least severe health state),  
x health state B (the most severe health state),  
then  
x sample HSUV for health state A as normal using a Normal distribution 
x sample a decrement (expected difference in HSUV for health states A and B) using a Beta 
distribution 
x calculate HSUV for health state B using the sampled values for health state A and the 
decrement 
 
 
6.2 Distributional forms used to characterise uncertainty in HSUVs 
HSUVs are bound by the limits of the index and are typically skewed with a minority of negative 
values.  Despite this, in the majority of cases, the uncertainty in the mean can be explored 
adequately by sampling from a normal distribution using the mean and standard error.  However, 
this method may produce implausible values outside the limits of the index when sampling for a 
relatively high or low HSUV in a patient level simulation.  In these cases it may be better to estimate 
a decrement to deduct from full health.  If the mean value is near the upper limit of the index, 
sampling from a lognormal or gamma distribution, would produce decrements on the interval (0, 
positive infinity).  Conversely, if the mean value is near the lower limit of the index, then scaling the 
standard beta distribution upwards using a height parameter (lambda) will provide sample values on 
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the interval (0, lambda).  Sampling from the proposed distribution prior to use in the decision model 
is good practice and histograms of sampled values should identify any anomalies in the sampled 
values. 
 
One occasion where sampled values outside the limits of the index tend to be generated is when 
using the results of poorly executed regression analyses.  Although simple linear functions obtained 
using ordinary least square regressions predict relatively accurate mean estimates, they can predict 
values outside the range of the index when covariates are involved (e.g. if the constant is greater 
than one and the age coefficient is negative and small, an expected value for a younger aged person 
could be greater than one) 
[1]
.  Any anomaly such as this will be compounded when sampling and 
again histograms of sampled values across all subgroups in the decision model should be examined.  
Similarly when using a statistical function to predict HSUVs based on a clinical measure of 
progression (e.g. health assessment questionnaire in rheumatoid arthritis), the sampled values at 
the extremes of the index / disease severity should be examined carefully. 
 
6.3 Univariate sensitivity analyses 
Univariate sensitivity analyses involving HSUVs ƚĞŶĚ ƚŽ ƵƐĞ ǀĂůƵĞƐ ƐĞůĞĐƚĞĚ Ăƚ ƚŚĞ ĂŶĂůǇƐƚƐ ?
discretion.  These could be the mean HSUV plus or minus the standard error of the mean or if this 
ŝƐŶ ?ƚĂǀĂŝůĂďůĞ ?ĂŶĂƌďŝƚƌĂƌǇǀĂůƵĞƐƵĐŚĂƐƉůƵƐŽƌŵŝŶƵƐ ? ?A?ŽĨƚŚĞŵĞĂŶ ?/ƚŝƐĞƋƵĂůůǇŝŵƉŽƌƚĂŶƚƚŽ
test results from the decision model using any additional relevant evidence identified in the 
literature searches.  This is particularly appropriate if there is no over-riding strong rational for the 
evidence selected for the base case, or when there is more than one published mapping function 
available in the literature.   
 
6.4 Threshold analyses 
Threshold analyses are informative to decision makers if the model results are very sensitive to the 
HSUVs used, or if the HSUVs are less than ideal.  The objective is to determine the minimum (or 
maximum) HSUV required for the model results to be considered cost-effective at a pre-defined cost 
per QALY threshold.  The threshold used will be setting specific and will typically be constrained to 
that used by the relevant policy decision makers.  Examples where a threshold analyses would be 
used are when adjusting the HSUVs in any way, using HSUVs from a similar condition (in the absence 
of any HSUVs in the condition of interest), incorporating detrimental effects associated with low 
grade adverse reactions, and when using evidence obtained from vignettes 
[28]
. 
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7. Reporting standards for HSUVs used in decision models 
One of the key issues commonly encountered when reviewing decision models is the poor reporting 
standards of the evidence used.  Transparency and clarity are required when describing the HSUVs 
used and the process used to reach the final inclusion decision.  This is particularly true when 
reporting the actual values used in the decision model and any associated adjustments made to 
these.   
 
In addition to the variables extracted in the systematic review or mapping study, the report 
describing the modelling methodology should include the mean (and uncertainty) HSUVs and any 
adjustments made to these, any values tested in sensitivity analyses and their rational, and the 
distributions used in probabilistic sensitivity analyses for each health state within the decision 
model.  Worked examples   of predicted HSUVs should be provided when using the results of 
regression models to demonstrate both the use of the statistical model and the possible range of 
predicted values.  The methodology used to adjust HSUVs should be clearly described and worked 
examples should be provided.  Variances and covariance matrices used in the probabilistic sensitivity 
analysis should be duly reported.  
 
8. Summary 
This article has discussed many of the issues encountered when using HSUVs in economic models 
together with suggested methodological approaches.  The most important detail is transparency in 
reporting standards for both the evidence used (together with justification), and any required 
 ?ĂĚũƵƐƚŵĞŶƚƐ ?ƚŽƚŚĞ,^hsƐƵƐĞĚǁŝƚŚŝŶƚŚĞŵŽĚĞů ?/ĨƌĞƉŽƌƚŝŶŐ standards are high, and a full range 
ŽĨƐĞŶƐŝƚŝǀŝƚǇĂŶĂůǇƐĞƐĂƌĞĐŽŶĚƵĐƚĞĚ ?ƚŚŝƐǁŝůůŝŶĐƌĞĂƐĞƌĞǀŝĞǁĞƌƐ ?ĐŽŶĨŝĚĞŶĐĞƚŚĂƚƚŚĞĞǀŝĚĞŶĐĞƵƐĞĚ
ŝƐƚŚĞŵŽƐƚĂƉƉƌŽƉƌŝĂƚĞĂǀĂŝůĂďůĞ ?ĂŶĚƉŽůŝĐǇĚĞĐŝƐŝŽŶŵĂŬĞƌƐ ?ĐŽŶĨŝĚĞŶĐĞŝŶƚŚĞƵŶĐĞƌƚĂŝŶƚǇĂƌŽƵŶĚ
the resulting ICER. 
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APPENDIX  
Box A.1  Worked example illustrating the suggested methodology for Example 2 in Box 2 
tĞŶĞĞĚĂŐĞ ?ŐĞŶĚĞƌĂĚũƵƐƚĞĚ,^hsƐĨŽƌƚŚĞŚĞĂůƚŚƐƚĂƚĞ ?ŶŽŚŝƐƚŽƌǇŽĨĐĂƌĚŝŽǀĂƐĐƵůĂƌĚŝƐĞĂƐĞ ?ďƵƚ
this evidence is not available in the public domain.  We know that the mean UK EQ-5D-3L HSUV for a 
63 year old male with a history of cardiovascular disease (but no recent cardiovascular event) is 0.78.   
We have a function that can be used to generate age/gender stratified norms for the UK EQ-5D-3L 
(Ara & Brazier, 2010):  
 ܧܳ ? ?ܦ ൌ  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ? ? ൈ ݈݉ܽ݁ െ  ?Ǥ ? ? ? ? ? ? ? ൈܽ݃݁ െ  ?Ǥ  ? ? ? ? ? ? ൈܽ݃݁H? 
 
The general population norms may be adjusted to account for the history of cardiovascular disease 
as follows: 
 
The expected general population norm for male aged 63 is:  ൌ  ?Ǥ ? ? ? ? ? ? ? ൅  ?Ǥ ? ? ? ? ? ? ? ? ? ൈሺ ሻ െ  ?Ǥ ? ? ? ? ? ? ? ൈ  ?െ  ?Ǥ ? ? ? ? ? ? ? ൈሺ ? ?ൈ  ? ?ሻ  ൌ  ?Ǥ ? ? ? ? 
 
The multiplier required to adjust the known HSUV for a 63 year old male with a history of 
cardiovascular disease (but no recent cardiovascular event) is: 
  ൌ  ? ?ൊ  ? ?  ൌ  ?Ǥ ? ? ?ൊ  ?Ǥ ? ? ? ?  ൌ  ?Ǥ ? ? ? ? 
 
dŚĞ ƌĞƋƵŝƌĞĚ ĂĚũƵƐƚĞĚ ǀĂůƵĞƐ ĨŽƌ ƚŚĞ ŚĞĂůƚŚ ƐƚĂƚĞ  ?ŶŽ ŚŝƐƚŽƌǇ ŽĨ ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ĚŝƐĞĂƐĞ ?  ?ŝ ?Ğ ? ƚŚĞ
baseline, are then estimated by multiplying the general population norms by the estimated 
multiplier.  The resulting baseline HSUVs used in the model are provided in Figure A.1.  The general 
population norms are plotted for illustration purposes only. 
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Table A.1  Age stratified health state utility values (EQ-5D) 
Age Male general population 
HSUVs 
Age/gender HSUVs values for history of 
cardiovascular disease 
20 0.9536 0.9027 
25 0.9449 0.8944 
30 0.9344 0.8845 
35 0.9223 0.8731 
40 0.9086 0.8601 
45 0.8932 0.8455 
50 0.8761 0.8294 
55 0.8574 0.8116 
60 0.8370 0.7923 
63 0.8240 0.7800 
65 0.8150 0.7715 
70 0.7913 0.7490 
75 0.7659 0.7250 
80 0.7389 0.6994 
 
 
Figure A.1  Age and gender adjusted baseline HSUVs for the health state history of cardiovascular 
disease 
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